Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 유경하 | * |
dc.contributor.author | 유은선 | * |
dc.date.accessioned | 2016-08-29T12:08:01Z | - |
dc.date.available | 2016-08-29T12:08:01Z | - |
dc.date.issued | 2016 | * |
dc.identifier.issn | 1083-8791 | * |
dc.identifier.issn | 1523-6536 | * |
dc.identifier.other | OAK-18985 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/231700 | - |
dc.description.abstract | Hematopoietic stem cell transplantation (HSCT) is a curative therapy for severe aplastic anemia (SAA); however, the optimal conditioning regimen for HSCT with an unrelated donor has not yet been defined. A previous study using a fludarabine (FLU), cyclophosphamide (Cy), and antithymocyte globulin (ATG) conditioning regimen (study A: 50 mg/kg Cy once daily i.v. on days -9, -8, -7, and -6; 30 mg/m(2) FLU once daily i.v. on days -5, -4, -3, and -2; and 2.5 mg/kg of ATG once daily i.v. on days -3, -2, and -1) demonstrated successful engraftment (100%) but had a high treatment-related mortality rate (32.1%). Therefore, given that Cy is more toxic than FLU, we performed a new phase II prospective study with a reduced-toxicity regimen (study B: 60 mg/kg Cy once daily i.v. on days -8 and -7; 40 mg/m(2) FLU once daily i.v. on days -6, -5, -4, -3, and -2; and 2.5 mg/kg ATG once daily i.v. on 3 days). Fifty-seven patients were enrolled in studies A (n = 28) and B (n = 29), and donor type hematologic recovery was achieved in all patients in both studies. The overall survival (OS) and event-free survival (EFS) rates of patients in study B was markedly improved compared with those in study A (OS: 96.7% versus 67.9%, respectively, P =.004; EFS: 93.3% versus 64.3%, respectively, P =.008). These data show that a reduced-toxicity conditioning regimen with FLU, Cy, and ATG may be an optimal regimen for SAA patients receiving unrelated donor HSCT. (C) 2016 American Society for Blood and Marrow Transplantation. | * |
dc.language | English | * |
dc.publisher | ELSEVIER SCIENCE INC | * |
dc.subject | Severe aplastic anemia | * |
dc.subject | Unrelated donor | * |
dc.subject | Fludarabine | * |
dc.subject | Cyclophosphamide | * |
dc.subject | Thymoglobulin | * |
dc.subject | Antithymocyte globulin (ATG) | * |
dc.title | Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies | * |
dc.type | Article | * |
dc.relation.issue | 8 | * |
dc.relation.volume | 22 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1455 | * |
dc.relation.lastpage | 1459 | * |
dc.relation.journaltitle | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | * |
dc.identifier.doi | 10.1016/j.bbmt.2016.04.003 | * |
dc.identifier.wosid | WOS:000380417400017 | * |
dc.identifier.scopusid | 2-s2.0-84976516781 | * |
dc.author.google | Kang, Hyoung Jin | * |
dc.author.google | Hong, Kyung Taek | * |
dc.author.google | Lee, Ji Won | * |
dc.author.google | Kim, Hyery | * |
dc.author.google | Park, Kyung Duk | * |
dc.author.google | Shin, Hee Young | * |
dc.author.google | Lee, Soo Hyun | * |
dc.author.google | Yoo, Keon Hee | * |
dc.author.google | Sung, Ki Woong | * |
dc.author.google | Koo, Hong Hoe | * |
dc.author.google | Lee, Jae Wook | * |
dc.author.google | Chung, Nak Gyun | * |
dc.author.google | Cho, Bin | * |
dc.author.google | Kim, Hack Ki | * |
dc.author.google | Koh, Kyung Nam | * |
dc.author.google | Im, Ho Joon | * |
dc.author.google | Seo, Jong Jin | * |
dc.author.google | Jung, Hyun Joo | * |
dc.author.google | Park, Jun Eun | * |
dc.author.google | Lee, Young Ho | * |
dc.author.google | Lim, Young Tak | * |
dc.author.google | Lim, Yeon Jung | * |
dc.author.google | Kim, Sun Young | * |
dc.author.google | Yoo, Eun Sun | * |
dc.author.google | Ryu, Kyung Ha | * |
dc.author.google | Lee, Jae Hee | * |
dc.author.google | Park, Jeong-A | * |
dc.author.google | Park, Sang Kyu | * |
dc.author.google | Ahn, Hyo Seop|Korean Soc Pediat Hematology-Oncol | * |
dc.contributor.scopusid | 유경하(14038236200) | * |
dc.contributor.scopusid | 유은선(20936704200) | * |
dc.date.modifydate | 20240118130224 | * |